Synapse - Gynecology Disease Management Team

Results (5144)

Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors

Meeting Abstract

Shapiro, G. I.; Basu, B.; El-Khoueiry, A.; Postel-Vinay, S.; Im, S. A.; Rha, S. Y.; Friedman, C. F.; Italiano, A.; Kim, Y. M.; Lim, M. C.; more...
Cancer Research (2022)

Fulltext@MSK | Save

A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132)

Meeting Abstract

Spigel, D.; Spira, A.; Zamarin, D.; McDermott, D. F.; Luke, J.; Heymach, J. V.; Previs, R.; Sullivan, R.; Gandhi, L.; Azrilevich, A.; more...
Cancer Research (2022)

Fulltext@MSK | Save

Epigenetic dysregulation from chromosomal transit in micronuclei

Meeting Abstract

Agustinus, A. S.; Raviram, R.; Dameracharla, B.; Luebeck, J.; Stransky, S.; Scipioni, L.; Myers, R. M.; Di Bona, M.; Duran, M.; Weigelt, B.; more...
Cancer Research (2022)

Fulltext@MSK | Save

First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors

Meeting Abstract

Carneiro, B. A.; Zamarin, D.; Marron, T.; Mehmi, I.; Patel, S. P.; Subbiah, V.; El-Khoueiry, A.; Grand, D.; Garcia-Reyes, K.; Goel, S.; more...
Cancer Research (2022)

Fulltext@MSK | Save

First-in-human trial of intravenous MEDI9253, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors

Meeting Abstract

Purroy, N.; Durham, N.; Phillips, M.; Hattersley, M. M.; Jung, L.; Davar, D.; Zamarin, D.; Johanns, T. M.; Puzanov, I.
Cancer Research (2022)

Fulltext@MSK | Save

Optimization of shared neoantigen vaccine design to increase vaccine potency: From bench to bedside and back

Meeting Abstract

Rappaport, A. R.; Palmer, C. D.; Shen, A.; Dominguez, C. X.; Hart, M. G.; Kraemer, L. D.; Koulavouth, S.; Marrali, M.; Jaroslavsky, J. R.; Nganje, C. N.; more...
Cancer Research (2022)

Fulltext@MSK | Save

T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade

Meeting Abstract

Muroyama, Y.; Manne, S.; Oldridge, D. A.; Wellhausen, N.; Greenplate, A. R.; Chilukuri, L.; Mathew, D.; Xu, C.; Herati, R. S.; Huang, A. C.; more...
Cancer Research (2022)

Fulltext@MSK | Save

Synthetic lethality by targeting ribonucleotide reductase in PP2A deficient uterine serous carcinoma

Meeting Abstract

O'Connor, C. M.; Taylor, S. E.; Miller, K. M.; Hurst, L.; Haanen, T. J.; Suhan, T. K.; Zawacki, K. P.; Noto, F. K.; Trako, J.; Mohan, A.; more...
Cancer Research (2022)

Fulltext@MSK | Save

Lower doses of self-amplifying mRNA drive superior neoantigen-specific CD8 T cell responses in cancer patients versus high doses

Meeting Abstract

Palmer, C. D.; Rappaport, A. R.; Hart, M. G.; Kraemer, L. D.; Kounlavouth, S.; Marrali, M.; Jaroslaysky, J. R.; Nganje, C. N.; Shen, A.; Boucher, G. R.; more...
Cancer Research (2022)

Fulltext@MSK | Save

Defining the balance of anti-viral and anti-tumor T cell responses to oncolytic virus therapy using single cell approaches

Meeting Abstract

Burman, B.; Ceglia, N.; Hirschhorn, D.; Budhu, S.; Mangarin, L.; Oseledchyk, A.; Bykov, Y.; McPherson, A.; Shah, S.; Wolchok, J.; more...
Cancer Research (2022)

Fulltext@MSK | Save